(Total Views: 366)
Posted On: 03/07/2021 8:35:07 PM
Post# of 145873
Quote:
Great data from CD 10 but too many mild patients.
The specific problem there was patients showing very low or no symptom scores. If there are no symptoms you can't show an improvement in symptoms. A phase 3 with a larger population and the proposed exclusion of those with symptom scores under 4 should show success given the sparse data we know.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)